Chargement en cours...
Dabrafenib and trametinib in BRAFV600E mutated glioma
BRAFV600E mutations have been identified in a number of glioma subtypes, most frequently in pleomorphic xanthoastrocytoma, ganglioglioma, pilocytic astrocytoma, and epithelioid glioblastoma. Although the development of BRAF inhibitors has dramatically improved the clinical outcome for patients with...
Enregistré dans:
| Publié dans: | CNS Oncol |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Future Medicine Ltd
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6004887/ https://ncbi.nlm.nih.gov/pubmed/28984141 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/cns-2017-0006 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|